Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

Curr Drug Targets. 2009 Feb;10(2):104-9. doi: 10.2174/138945009787354539.


The recombinant CD3 immunotoxin, A-dmDT(390)-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3epsilon monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

Publication types

  • Review

MeSH terms

  • Aged
  • CD3 Complex / immunology
  • Diphtheria Toxin / adverse effects
  • Diphtheria Toxin / therapeutic use*
  • Drug Delivery Systems
  • Female
  • Humans
  • Immunotoxins / adverse effects
  • Immunotoxins / therapeutic use*
  • Lymphoma, T-Cell / therapy*
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use
  • Skin Neoplasms / therapy*


  • CD3 Complex
  • Diphtheria Toxin
  • Immunotoxins
  • Recombinant Fusion Proteins